- |||||||||| Humira (adalimumab) / Eisai, AbbVie
Sympathetic ophthalmia after ruthenium plaque brachytherapy for iris melanoma () - Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1130;
It represents an autoimmune T-cell-mediated response against uveal antigenic protein, which usually is exposed after a traumatic or surgical injury involving the uvea. The risk of developing sympathetic ophthalmia after charged-particle therapy in the absence of a penetrating uveal tract injury is minimal, but possible.
- |||||||||| Stelara (ustekinumab) / J&J, Enbrel (etanercept) / Takeda, Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal, HEOR, Real-World Evidence: Biologic treatment sequences for plaque psoriasis: a cost-utility analysis based on 10 years of Dutch real-world evidence from BioCAPTURE. (Pubmed Central) - Sep 26, 2019
The order in which biologics are used influences treatment cost-effectiveness, both in terms of costs and health effects. Initiation of a biologic treatment sequence for psoriasis may best be done with adalimumab or ustekinumab; etanercept seems less optimal from a health-economic perspective.
- |||||||||| Review, Journal, HEOR: A Systematic Review of the Cost-Effectiveness of Biologics for Ulcerative Colitis. (Pubmed Central) - Sep 26, 2019
Clinical outcomes are transferable to other countries and could be generalized; however, cost inputs are country-specific and therefore limit the transferability and generalizability of conclusions. The key drivers and variables that showed the greatest effect on the analysis results were utility weights and clinical parameters.
- |||||||||| Review, Journal: Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. (Pubmed Central) - Sep 26, 2019
Consistent with its conclusion regarding clinical effectiveness, the Appraisal Committee concluded that the cost effectiveness of ixekizumab for treating moderate-to-severe plaque psoriasis was similar to that of other biological treatments, already recommended in previous National Institute for Health and Care Excellence guidance. The committee concluded that the incremental cost-effectiveness ratio was within the range that could be considered a cost-effective use of National Health Service resources.
- |||||||||| Review, Journal: Baricitinib for Previously Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. (Pubmed Central) - Sep 26, 2019
The clinical-effectiveness evidence in the CS for BARI was based predominantly on three randomised controlled trials comparing the efficacy of BARI against adalimumab or placebo, as well as one long-term extension study...The company submitted a de novo discrete event simulation model that analysed the incremental cost-effectiveness of BARI versus its comparators for the treatment of RA from the perspective of the National Health Service (NHS) in four different populations: (1) cDMARD-IR patients with moderate RA, defined as a 28-Joint Disease Activity Score (DAS28) > 3.2 and no more than 5.1; (2) cDMARD-IR patients with severe RA (defined as a DAS28 > 5.1); (3) TNFi-IR patients with severe RA for whom rituximab (RTX) was eligible; and (4) TNFi-IR patients with severe RA for whom RTX in combination with methotrexate (MTX) is contraindicated or not tolerated...In the cDMARD-IR population with severe RA, BARI in combination with MTX dominated all comparators except for certolizumab pegol (CTZ) in combination with MTX, with the ICER of CTZ in combination with MTX compared with BARI in combination with MTX estimated to be £18,400 per QALY gained...In the TNFi-IR population with severe RA for whom RTX in combination with MTX is contraindicated or not tolerated, BARI in combination with MTX dominated golimumab in combination with MTX and was less effective and less expensive than the remaining comparators...The programming error that affected the PSA of the severe cDMARD-IR population had only a minimal impact on the results, while the error affecting the severe TNFi-IR RTX-ineligible population resulted in markedly higher costs and QALYs gained for the affected comparators but did not substantially modify the conclusions of the analysis. The NICE Appraisal Committee concluded that BARI in combination with MTX or as monotherapy is a cost-effective use of NHS resources in patients with severe RA, except in TNFi-IR patients who are RTX-eligible.
- |||||||||| Xeljanz (tofacitinib) / Pfizer, Humira (adalimumab) / Eisai, AbbVie, Rituxan (rituximab) / Roche, Biogen
Review, Journal: Tofacitinib for Treating Rheumatoid Arthritis After the Failure of Disease-Modifying Anti-rheumatic Drugs: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. (Pubmed Central) - Sep 26, 2019
All four RCTs compared TOF with placebo plus cDMARDs, one RCT also included adalimumab as a comparator...The company submitted a de novo model that assessed the cost-effectiveness of TOF versus its comparators in six different populations: (1) cDMARD-IR with severe RA; (2) cDMARD-IR with severe RA for whom MTX is contraindicated or not tolerated; (3) bDMARD-IR; (4) bDMARD-IR for whom rituximab (RTX) is contraindicated or not tolerated; (5) bDMARD-IR for whom MTX is contraindicated or not tolerated; and, (6) cDMARD-IR with moderate RA...TOF plus MTX is also recommended as an option for adults whose disease has responded inadequately to, or who cannot have, other DMARDs, including at least one bDMARD, only if (1) disease is severe, (2) they cannot have RTX, and (3) the company provides TOF with the discount agreed in the PAS. For patients who are intolerant of MTX, or where MTX is contraindicated, TOF monotherapy is recommended where TOF plus MTX would be recommended.
- |||||||||| Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
STUBBORN SARCOIDOSIS: A CLASSIC CASE OF LUPUS PERNIO (Ernest N. Morial Convention Center - Exhibit Hall - Poster Area 2) - Sep 25, 2019 - Abstract #CHEST2019CHEST_3618;
Hydroxychloroquine 200mg daily was then initiated, and due to progression of her cutaneous disease, this was increased to 400mg daily with topical Clobetasol...After one year of therapy on Infliximab/Hydroxychloroquine there was dramatic improvement in her cutaneous lesions, and she was transitioned to her current Adalimumab regimen.Sarcoidosis is a multi-organ disease of unknown etiology characterized by noncaseating granulomas found in tissue...As seen in a few small case series of refractory cutaneous sarcoid, we present a case of lupus pernio showing dramatic results after one year of treatment with Infliximab. This should be considered in select refractory cases.
- |||||||||| Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
SARCOID ACRO-OSTEOLYSIS (Ernest N. Morial Convention Center - Exhibit Hall - Poster Area 2) - Sep 25, 2019 - Abstract #CHEST2019CHEST_3609;
Acro-osteolysis is the resorption of the distal phalanx and can be a rare manifestation of sarcoid involving the bones. Immunosuppression with agents such as corticosteroids and methotrexate are the mainstay treatment.Biologic agents such as infliximab and adalimumab may be used in aggressive or refractory cases.
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
THE CRIPPLING EFFECT OF MOLLY: RAPIDLY PROGRESSIVE MULTI-ORGAN FAILURE (Ernest N. Morial Convention Center - Exhibit Hall - Poster Area 4) - Sep 25, 2019 - Abstract #CHEST2019CHEST_3507;
Medical staff should be cognizant of synthetic drug intoxications and consider it as one of their differentials when an individual presents with multiple organ derangements. Protocols should also be implemented at hospitals to address drug overdose especially with the increasing amounts of deaths associated with drug overdose.
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
PULMONARY MANIFESTATIONS OF CROHN'S DISEASE (Ernest N. Morial Convention Center - Exhibit Hall - Poster Area 2) - Sep 25, 2019 - Abstract #CHEST2019CHEST_2796;
It is imperative to obtain biopsy results, due to the detrimental effects of withdrawing disease modifying medications and worsening CD activity. Spontaneous resolution can occur with pulmonary CD, such as in our patient.
- |||||||||| Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
COEXISTENT TAKAYASU ARTERITIS AND SARCOIDOSIS: A CASE REPORT (Ernest N. Morial Convention Center - Exhibit Hall - Poster Area 4) - Sep 25, 2019 - Abstract #CHEST2019CHEST_2485;
Over the subsequent 14 years she had been treated with corticosteroids, cyclophosphamide, infliximab, adalimumab, and methotrexate...She was receiving prednisone 10mg daily and methotrexate 25mg subcutaneously weekly...Given the prevalence of these diseases, concomitant development of these two diseases is unlikely to be by chance alone and probably reflects a unifying mechanism. Clinicians should be aware of this association.
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma, Humira (adalimumab) / Eisai, AbbVie, Rituxan (rituximab) / Roche, Biogen
RAPIDLY PROGRESSIVE RHEUMATOID LUNG DISEASE (Ernest N. Morial Convention Center - Exhibit Hall - Poster Area 1) - Sep 25, 2019 - Abstract #CHEST2019CHEST_2473;
After the biopsy, she continued to have dyspnea and hypoxia along with flares of her arthritis requiring supplemental oxygen as well as chronic prednisone, increased doses of Humira, and a trial of tocilizumab...At this time, she was switched to mycophenolate mofetil and rituximab and continued on prednisone...This case emphasizes the importance of recognizing the pulmonary complications associated with RA and their potential to progress and worsen over time, even in an atypical fashion. Adequate treatment and early referral to a transplant center is essential for all patients with rapidly progressive interstitial lung disease.
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
ADALIMUMAB (HUMIRA) AND THE RISK OF RECURRENT VENOUS THROMBOEMBOLISM (Ernest N. Morial Convention Center - Exhibit Hall - Poster Area 5) - Sep 25, 2019 - Abstract #CHEST2019CHEST_1899;
Patient was discharged on apixaban 10mg BID for 6 days to switch to 5mg BID for 6 months. This case demonstrates the need for evaluation of anticoagulation guidelines in patients taking Adalimumab due to the persistence of hyper-coagulable state after previous thromboembolic events.
- |||||||||| Humira (adalimumab) / Eisai, AbbVie, Avelox (moxifloxacin) / Bayer
DISSEMINATED TB WITH PERITONEAL INVOLVEMENT ASSOCIATED WITH ADALIMUMAB THERAPY (Ernest N. Morial Convention Center - Exhibit Hall - Poster Area 2) - Sep 25, 2019 - Abstract #CHEST2019CHEST_1564;
We report a case of a disseminated TB with peritoneal involvement in a patient on adalimumab for rheumatoid arthritis (RA).Case Presentation:A 62 year-old Asian female with RA on adalimumab and methotrexate presented with dyspnea, nonproductive cough, fever, and abdominal pain after recent treatment with azithromycin for suspected pneumonia on outpatient chest radiograph. Atypical TB infection should remain high on the differential in adalimumab-treated patients presenting with peritoneal infiltration.
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
Trial completion date, Trial primary completion date: Videocapillaroscopy Assessment During Systemic Agent Therapy in Psoriasis (clinicaltrials.gov) - Sep 23, 2019
P=N/A, N=30, Recruiting,
Active, not recruiting --> Completed Trial completion date: Jul 2019 --> Dec 2019 | Trial primary completion date: Jul 2019 --> Dec 2019
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal: Severe lymphopenia in a patient with Crohn's disease (Pubmed Central) - Sep 22, 2019
Lymphocytopenia is frequently observed as a side effect of immunosuppressive therapy. This case illustrates that lymphocytopenia may also occur in relation to Crohn's disease activity as an extraintestinal manifestation and may then be efficiently treated by escalation of immunosuppressive therapy.
- |||||||||| Review, Journal: Sarilumab for Previously-Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. (Pubmed Central) - Sep 22, 2019
The clinical effectiveness evidence in the company's submission for SAR was based predominantly on five randomised controlled trials comparing the efficacy of SAR against adalimumab, tocilizumab or placebo...The company submitted a Markov model that assessed the cost-effectiveness of SAR from the perspective of the National Health Service (NHS) and Personal Social Services in seven different populations: (1) patients with severe RA who have had an inadequate response to cDMARDs (cDMARD-IR); (2) cDMARD-IR patients with severe RA for whom methotrexate (MTX) is contraindicated or not tolerated; (3) patients with severe RA who have had an inadequate response to a TNFi (TNFi-IR); (4) TNFi-IR patients with severe RA for whom rituximab (RTX) is not an option; (5) TNFi-IR patients with severe RA for whom MTX is contraindicated or not tolerated; (6) TNFi-IR patients after RTX; and (7) cDMARD-IR patients with moderate RA whose 28-joint Disease Activity Score (DAS28) is between 4.0 and 5.1...The ICERs estimated by the ERG's exploratory analyses for SAR + MTX increased to £171,466 per QALY gained when compared with RTX + MTX in TNFi-IR patients who are RTX eligible, and to £63,438 per QALY gained when compared with MTX in patients with moderate RA and a DAS28 of > 4.0. The Appraisal Committee concluded that SAR in combination with MTX or as monotherapy is a cost-effective use of NHS resources in the considered populations, except in TNFi-IR patients who are RTX eligible and in patients with moderate RA and a DAS28 of > 4.0.
- |||||||||| Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
Use of Tumor Necrosis Factor Alpha Inhibitors for Treatment of Refractory Cardiac Sarcoidosis (Zone 2, Science and Technology Hall) - Sep 20, 2019 - Abstract #AHA2019AHA_8124;
Twenty patients (30% female, 25% African American; mean age at CS diagnosis 49 ± 11 yrs) were treated with a TNFa inhibitor (19 infliximab, 1 adalimumab)...Nineteen patients (95%) were treated with corticosteroids and 13 (65%) with a SSA (6 azathioprine, 5 mycophenolate mofetil, 2 methotrexate, 9 ≥ 2 SSA)... In appropriately selected patients with refractory CS, TNF alpha inhibitors may be a useful adjunctive treatment option.
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
Review, Journal: Evidence-Based Treatment for Uveitis. (Pubmed Central) - Sep 19, 2019
In this review, we reported the current evidence-based treatments for non-infectious uveitis in pediatric and adult patients with particular attention to the biologic response modifier treatment options. Important multicenter studies have demonstrated the efficacy of adalimumab, both in adults (VISUAL I, VISUAL II, VISUAL III) and in children (SYCAMORE, ADJUVITE), while for other agents data are still scarce.
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
Intraocular lens implantation in children with cataracts due to chronic uveitis (Free Paper Forum: Podium 2) - Sep 16, 2019 - Abstract #ESCRS2019ESCRS_658;
Cataract extraction in children with chronic uveitis can be complicated. Appropriate surgical technique, preoperative and postoperative immunosuppression and meticulous follow up is mandatory for good postoperative outcome.
- |||||||||| Clinical, Review, Journal: Maneuvering Clinical Pathways for Crohn's Disease. (Pubmed Central) - Sep 16, 2019
Patient with inadequate response should have their trough level checked and therapy optimized. Therapeutic prophylaxis for post-operative recurrence should be based on patient's risk factors for recurrence.
- |||||||||| Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
Trial completion: FART: Faecal Analyses in Rheumatoid Arthritis Therapy (clinicaltrials.gov) - Sep 16, 2019
P=N/A, N=50, Completed,
Therapeutic prophylaxis for post-operative recurrence should be based on patient's risk factors for recurrence. Active, not recruiting --> Completed
- |||||||||| Stelara (ustekinumab) / J&J, Enbrel (etanercept) / Takeda, Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
Clinical, Review, Journal: Biologic Treatment Options for Pediatric Psoriasis and Atopic Dermatitis. (Pubmed Central) - Sep 15, 2019
Given the high morbidity associated with pediatric atopic dermatitis and psoriasis, there is a need for more treatment options. Further research and post-marketing registries are needed to extend the use of biologics into pediatric patients.
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal: Case of drug-induced interstitial lung disease secondary to adalimumab. (Pubmed Central) - Sep 14, 2019
In conjunction with BMJ Case Reports, DTB will feature occasional drug-related cases that are likely to be of interest to readers. These will include cases that involve recently marketed drugs for which there is limited knowledge of adverse effects and cases that highlight unusual reactions to drugs that have been marketed for several years.
- |||||||||| Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
Review, Journal: Evaluation of de-escalation of anti-TNF-α therapy in inflammatory bowel disease. (Pubmed Central) - Sep 14, 2019
After more than a decade using these therapies the question arises about whether there is an appropriate time to suspend these therapies, and how this should be done. This review aims to evaluate the current evidence on these topics concerning anti-tumour necrosis factor α therapies, and eventually identify conditions and subgroups of patients that could potentially be candidates for withdrawal.
|
